14 July 2015 : Case report
Graft-versus-Host Disease after Liver Transplantation: A Single-Center Case Series
Hussien ElsiesyAEF, Abeer IbrahimBEF, Khaled SelimDF, Mohammed Al SebayelCF, Dieter BroeringAF, Waleed Al HamoudiCDF, Rania Al AriehB, Faisal AbaalkhailAEFDOI: 10.12659/AOT.893616
Ann Transplant 2015; 20:397-401
Abstract
BACKGROUND: Graft versus host disease (GVHD) is a rare complication following liver transplantation (LT) and has high mortality. We describe our single-center experience with 6 cases of GVHD diagnosed over a period of 14 years in a total of 604 liver transplant recipients – 283 deceased donor liver transplants (DDLT) and 321 living-related liver transplants (LDLT).
CASE REPORT: We report a case series of 6 patients with acute GVHD after liver transplantation from May 2001 to December 2014. Five cases were males; age 51–67 years (average 61). The time from transplantation until clinical presentation of GVHD ranged from 36 to 140 days, with average duration of 72 days. All cases had diarrhea and pancytopenia, 4 out of 5 presented with erythematous skin rashes, and 2 had cytomegalovirus colitis. GVHD was confirmed by skin biopsies, engraftment profile from bone marrow biopsy, and sigmoid colon biopsy. Treatment strategies included use of corticosteroids in 4 cases, stopping immunosuppression in 1 case, and no treatment in 1 case with mild disease. Five patients died between 18 to 65 days from clinical presentation (average 43 days) and 1 patient with mild GVHD is doing well 290 days after clinical presentation.
CONCLUSIONS: GVHD is a rare complication after liver transplantation that needs a high index of suspicion in patients who develop rash, diarrhea, or sever pancytopenia. There is no consensus on the best treatment regimen and mortality remains high.
Keywords: Graft vs Host Disease, Immunosuppression, Liver Transplantation
In Press
Original article
Effect of Medical Accessibility on Long-Term Survival in Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.944839
Original article
Lung Transplant Success in COVID-19 Patients Requiring V-V ECMO: One-Year Follow-UpAnn Transplant In Press; DOI: 10.12659/AOT.946088
Most Viewed Current Articles
05 Apr 2022 : Original article 13,221
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 10,677
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
12 Jan 2022 : Original article 9,822
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
15 Mar 2022 : Case report 7,535
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860